Replimune (REPL) Non-Current Debt (2019 - 2026)
Replimune (REPL) posted Non-Current Debt of $83.3 million for Q1 2026, up 74.91% sequentially from $47.6 million in Q4 2025, and up 79.63% YoY from $46.4 million in Q1 2025.
Replimune (REPL) Non-Current Debt (2019 - 2026) Analysis & Trends
Replimune has reported Non-Current Debt for 7 years, with the latest figure at $83.3 million in Q1 2026.
- Quarterly Non-Current Debt rose 79.63% year-over-year to $83.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $83.3 million (up 79.63% YoY) and the FY2026 annual result came in at $83.3 million, up 79.63% from the prior year.
- Non-Current Debt grew to $83.3 million in Q1 2026 per REPL's latest filing, from $47.6 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $83.3 million in Q1 2026 and troughed at $28.4 million in Q4 2022.
- A 5-year average of $43.7 million and a median of $45.4 million in 2024 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2024 and 2026: Non-Current Debt increased 3.43% in 2024, then soared 79.63% in 2026.
- Over 5 years, Non-Current Debt stood at $28.4 million in 2022, then surged by 56.51% to $44.4 million in 2023, then increased by 3.43% to $46.0 million in 2024, then grew by 3.63% to $47.6 million in 2025, then soared by 74.91% to $83.3 million in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $83.3 million, $47.6 million, and $47.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Replimune | 1.24 Bn | 1.24 Bn | - | 83.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 83.31 Mn |
| Dec 31, 2025 | 47.63 Mn |
| Sep 30, 2025 | 47.21 Mn |
| Jun 30, 2025 | 46.79 Mn |
| Mar 31, 2025 | 46.38 Mn |
| Dec 31, 2024 | 45.96 Mn |
| Sep 30, 2024 | 45.57 Mn |
| Jun 30, 2024 | 45.19 Mn |
| Mar 31, 2024 | 44.81 Mn |
| Dec 31, 2023 | 44.43 Mn |
| Sep 30, 2023 | 29.16 Mn |
| Jun 30, 2023 | 28.91 Mn |
| Mar 31, 2023 | 28.65 Mn |
| Dec 31, 2022 | 28.39 Mn |
| Sep 30, 2020 | 9.83 Mn |
| Jun 30, 2020 | 9.76 Mn |
| Mar 31, 2020 | 9.80 Mn |
| Dec 31, 2019 | 9.74 Mn |
| Sep 30, 2019 | 9.66 Mn |